|
Report No. : |
341464 |
|
Report Date : |
19.09.2015 |
IDENTIFICATION DETAILS
|
Name : |
LABORATORIO CHILE SA |
|
|
|
|
Registered Office : |
Avenida Marathon 1315 Ñuñoa Santiago |
|
|
|
|
Country : |
Chile |
|
|
|
|
Date of Incorporation : |
1896 |
|
|
|
|
Legal Form : |
Sociedad Anónima |
|
|
|
|
Line of Business : |
Manufacture, Import and Distribution of Pharmaceutical Items. |
|
|
|
|
No. of Employees : |
900 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Chile |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
CHILE - ECONOMIC OVERVIEW
Chile has a market-oriented economy characterized by a high
level of foreign trade and a reputation for strong financial institutions and
sound policy that have given it the strongest sovereign bond rating in South
America. Exports of goods and services account for approximately one-third of
GDP, with commodities making up some three-quarters of total exports. Copper
alone provides 19% of government revenue. From 2003 through 2013, real growth
averaged almost 5% per year, despite the slight contraction in 2009 that
resulted from the global financial crisis. Growth slowed to 4.2% in 2014. Chile
deepened its longstanding commitment to trade liberalization with the signing
of a free trade agreement with the US, which took effect on 1 January 2004.
Chile has 22 trade agreements covering 60 countries including agreements with
the European Union, Mercosur, China, India, South Korea, and Mexico. Chile has
joined the United States and 10 other countries in negotiating the Trans-Pacific
Partnership trade agreement. The Chilean Government has generally followed a
countercyclical fiscal policy, accumulating surpluses in sovereign wealth funds
during periods of high copper prices and economic growth, and generally
allowing deficit spending only during periods of low copper prices and growth.
As of 31 December 2012, those sovereign wealth funds - kept mostly outside the
country and separate from Central Bank reserves - amounted to more than $20.9
billion. Chile used these funds to finance fiscal stimulus packages during the
2009 economic downturn. In May 2010 Chile signed the OECD Convention, becoming
the first South American country to join the OECD. In 2014, President Michelle
BACHELET introduced tax reforms aimed at delivering her campaign promise to
fight inequality and to provide access to education and health care. The
reforms are expected to generate additional tax revenues equal to 3% of Chile’s
GDP, mostly by increasing corporate tax rates to OECD averages.
|
Source
: CIA |
STATUTORY INFORMATION
|
|
|
Legal Name: |
LABORATORIO CHILE SA |
|
Trade Name: |
LABORATORIO CHILE |
|
RUT: |
77596940-7 |
|
Date Created: |
1896 |
|
Date Incorporated: |
25/05/2001 |
|
Legal Address: |
Avenida Marathon 1315 Ñuñoa Santiago Chile |
|
Operative Address: |
Avenida Marathon 1315 Ñuñoa Santiago Chile |
|
Telephone: |
(56) 02 2365 5000 |
|
Fax: |
(56-2) 2365 5100 |
|
Legal Form: |
Sociedad Anónima |
|
Email: |
|
|
Registered in: |
Chile |
|
Website: |
|
|
Contact: |
Hernan E. Pfeifer Frenz |
|
Staff: |
900 |
|
Activity: |
Pharmaceutical Manufacturing Industry |
|
|
|
|
BANK DATA |
Banco Santander Rio |
|
|
|
|
|
The company does not disclose its banking data |
HISTORY
|
|
|
|
The company started business in 1896 |
|
|
|
PRINCIPAL ACTIVITY
|
|
|
|
The company is dedicated to the manufacture, import and distribution of
pharmaceutical items. |
|
Products/Services description: |
Antibiotics |
|
Brands: |
Some brands are: |
|
Clients: |
Mather Company Srl |
|
Suppliers: |
Syntofarma S A |
|
Operations area: |
National and International |
|
The company imports from |
Colombia |
|
The company exports to |
Latin America |
|
The subject employs |
900 employees |
|
Payments: |
No Complaints |
|
|
|
LOCATION
|
|
|
Headquarters : |
Avenida Marathon 1315 Ñuñoa Santiago Chile |
|
Branches: |
Camino Melipiga 9978, Santiago Chile |
|
Industry: |
Companies in this industry manufacture and
process pharmaceutical products. |
|
|
|
GROUP STRUCTURE AND
SUBSIDIARY COMPANIES
|
|
|
Listed at the stock exchange: |
NO |
|
Capital: |
NA |
|
Shareholders %: |
The company is a subsidiary of: |
|
Management: |
Eduardo Heredia Pena, Director |
|
|
|
FINANCIAL INFORMATION
|
|
|
|
The company does not make its financial statements public. |
|
|
|
|
|
|
|
Imports in US$ |
|
|
Year |
Total |
|
2013 |
US$ 43,078,842 |
|
2012 |
US$ 44,997,353 |
|
2011 |
US$ 40,929,494 |
|
2010 |
US$ 37,622,175 |
|
2009 |
US$ 32,210,778 |
|
2008 |
US$ 29,807,352 |
|
|
|
|
|
|
|
Exports in US$ |
|
|
Year |
Total |
|
2013 |
US$ 21,326,561 |
|
2012 |
US$ 23,882,766 |
|
2011 |
US$ 24,647,886 |
|
2010 |
US$ 17,851,280 |
|
2009 |
US$ 15,419,661 |
|
2008 |
US$ 15,081,847 |
|
|
|
LEGAL FILINGS
|
|
|
|
There are no legal connected to the subject |
|
|
|
SUMMARY
|
|
|
|
The company is dedicated to the manufacture, import and distribution
of pharmaceutical items. The company has a large sized structure and is held by one of the
leaders in the industry: Teva Pharmaceuticals. The subject’s exports and imports amounts are high and show no
negative. |
|
|
|
RISK INFORMATION
|
|
|
DEBTS |
Controlled |
|
PAYMENTS |
No Complaints |
|
CASH FLOW |
Normal |
|
STATUS |
Active |
|
|
|
|
INTERVIEW |
|
|
NAME |
Daniela |
|
POSITION |
Administrative |
|
COMMENTS |
She confirmed address, branches, general director, parent company and
staff. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.65.92 |
|
|
1 |
Rs.102.75 |
|
Euro |
1 |
Rs.75.13 |
INFORMATION DETAILS
|
Analysis Done by
: |
RAS |
|
|
|
|
Report Prepared
by : |
ANK |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as
a reference to assess SC’s credit risk and to set the amount of credit to be
extended. It is calculated from a composite of weighted scores obtained from each
of the major sections of this report. The assessed factors and their relative
weights (as indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.